Combination of CsA, MTX and low-dose, short-course mycophenolate mofetil for GVHD prophylaxis

Bone Marrow Transplantation
Y LaiJ Liang

Abstract

In an effort to reduce the incidence and severity of acute GVHD (aGVHD), we have developed a new prophylaxis regimen combining cyclosporine and MTX with a short 30-day course of low-dose (500 mg per day) mycophenolate mofetil. This regimen was studied prospectively 100 patients undergoing HLA-matched and 1-antigen-mismatched allogeneic peripheral blood SCT from related donors. The cumulative incidence of aGVHD was 16% (grades II-IV (9.5%) and grades III-IV (1%)). The cumulative incidence of chronic GVHD (cGVHD) was 53% with 28% extensive cGVHD. The cumulative incidence of transplant-related mortality at 100 days and 3 years were 6 and 13%. The estimated probabilities of disease-free survival at 3 years in standard- and high-risk patients were 77 and 30%, respectively (P<0.0001). The estimated probabilities of overall survival at 3 years in standard- and high-risk patients were 77 and 37%, respectively (P<0.0001). These data show a substantial decrease in the risk of developing aGVHD without an increase in relapse or any adverse impact on survival in standard-risk patients.

References

Nov 30, 1993·Annals of the New York Academy of Sciences·A C AllisonE M Eugui
Jul 20, 2002·Blood·Norbert SchmitzUNKNOWN European Group for Blood and Marrow Transplantation
Nov 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vanderson RochaUNKNOWN Acute Leukemia Working Party of the European Blood and Marrow Transplant Registry
Dec 19, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·O RingdénF Frassoni
Mar 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frédéric BaronRainer Storb
Jun 29, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Richard A NashRainer Storb
Jul 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN Stem Cell Trialists' Collaborative Group
Feb 8, 2006·Current Opinion in Oncology·Javier Bolaños-Meade
Apr 22, 2006·Therapeutic Drug Monitoring·Teun van GelderRichard D Mamelok
Aug 2, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Norbert-Claude GorinUNKNOWN Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation
Nov 23, 2006·Transplantation Proceedings·M KaushikM L Nicholson

❮ Previous
Next ❯

Citations

Mar 20, 2012·Journal of Hematology & Oncology·Meng Lv, Xiao-Jun Huang
Jul 13, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Weijie CaoHe Huang
Jul 28, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Immacolata AttolicoAttilio Olivieri
Mar 23, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Xiao-Jun Huang, Ying-Jun Chang
Feb 9, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yuzhen LiangYizhen Zhou
Oct 3, 2009·British Journal of Haematology·Vanderson RochaUNKNOWN Eurocord-Netcord registry and European Blood and Marrow Transplant group
Jan 7, 2017·World Journal of Transplantation·Nosha Farhadfar, William J Hogan
Mar 2, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Y U WangHuang Xiao-Jun
Aug 12, 2020·Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation·Mani RamziHourvash Haghighinejad

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.